Literature DB >> 2659104

Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer.

J C Buckner1, J N Ingle, L K Everson, J R O'Fallon, S A Cullinan, D L Ahmann, J E Krook, D M Pfeifle.   

Abstract

We have evaluated the results of salvage systemic therapy in 257 patients with breast cancer recurrent after surgical adjuvant treatment with cyclophosphamide, fluorouracil, and prednisone (CFP) with or without tamoxifen. The overall objective response rate to salvage hormonal therapy was 29% (47 responses in 161 patients) and to salvage chemotherapy was 28% (43 responses in 156 patients). Response rates to salvage chemotherapy were similar whether or not prior salvage hormonal therapy or local modalities had been administered. Retreatment with CFP as a salvage chemotherapy yielded responses in 11 of 44 patients (25%). Response rates were similar for patients who began salvage CFP less than or equal to 12 months or greater than 12 months after completion of adjuvant CFP. We conclude that when this unselected population of patients failing adjuvant CFP is considered, 1) response rates to salvage chemotherapy were low regardless of whether or not prior salvage hormonal or local therapies were given, 2) repeating adjuvant chemotherapy (CFP) following relapse produced a low response rate, and 3) response rates to salvage hormonal therapy were low, but on the order of those observed in patients with advanced disease unselected by estrogen receptor status who are treated with first line hormonal maneuvers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2659104     DOI: 10.1007/bf01806525

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

1.  A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy.

Authors:  D L Ahmann; J R O'Fallon; P W Scanlon; W S Payne; H F Bisel; J H Edmonson; S Frytak; R G Hahn; J N Ingle; J Rubin; E T Creagan
Journal:  Am J Clin Oncol       Date:  1982-08       Impact factor: 2.339

2.  Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer.

Authors:  D L Ahmann; P W Scanlon; H F Bisel; J H Edmonson; S Frytak; W S Payne; J R O'Fallon; R G Hahn; J N Ingle; M J O'Connell; J Rubin
Journal:  Lancet       Date:  1978-04-29       Impact factor: 79.321

3.  Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer.

Authors:  J N Ingle; L K Everson; H S Wieand; J K Martin; H J Votava; L E Wold; J E Krook; S A Cullinan; J K Paulsen; D I Twito
Journal:  J Clin Oncol       Date:  1988-09       Impact factor: 44.544

4.  The response to further chemotherapy in patients with carcinoma of the breast who progressed while receiving adjuvant therapy.

Authors:  D M Morris; E G Elias; M S Didolkar; S D Brown
Journal:  J Surg Oncol       Date:  1985-07       Impact factor: 3.454

5.  Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens.

Authors:  A U Buzdar; S S Legha; G N Hortobagyi; H Y Yap; C L Wiseman; A Distefano; F C Schell; B C Barnes; L T Campos; G R Blumenschein
Journal:  Cancer       Date:  1981-06-15       Impact factor: 6.860

6.  Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.

Authors:  G Bonadonna; P Valagussa; A Rossi; G Tancini; C Brambilla; M Zambetti; U Veronesi
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

7.  Systemic therapy of metastatic breast cancer: a review of the current trends.

Authors:  S S Legha; G R Blumenschein
Journal:  Oncology       Date:  1982       Impact factor: 2.935

Review 8.  Chemotherapy of breast cancer: current views and results.

Authors:  G Bonadonna; P Valagussa
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-03       Impact factor: 7.038

9.  Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy.

Authors:  P Valagussa; G Tancini; G Bonadonna
Journal:  Cancer       Date:  1986-10-01       Impact factor: 6.860

10.  Salvage treatment of patients relapsing after breast cancer adjuvant chemotherapy.

Authors:  A G Wendt; S E Jones; S E Salmon
Journal:  Cancer Treat Rep       Date:  1980 Feb-Mar
  10 in total
  2 in total

Review 1.  North Central Cancer Treatment Group--achievements and perspectives.

Authors:  Axel Grothey; Alex A Adjei; Steve R Alberts; Edith A Perez; Kurt A Jaeckle; Charles L Loprinzi; Daniel J Sargent; Jeff A Sloan; Jan C Buckner
Journal:  Semin Oncol       Date:  2008-10       Impact factor: 4.929

Review 2.  Management of metastatic breast cancer.

Authors:  K Wong; I C Henderson
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.